New drug cocktail aims to shrink NF1 tumors

NCT ID NCT06502171

Not yet recruiting Disease control Sponsor: Girish Dhall, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether two cancer drugs, cabozantinib and selumetinib, can safely shrink plexiform neurofibromas in people aged 16 and older with neurofibromatosis type 1 (NF1). About 30 participants will receive the combination daily. The study first finds the safest dose, then checks if tumors shrink by at least 20% on MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib and selumetinib
What this could lead to: If this combination works, it could offer a new treatment option to shrink or slow growth of painful nerve tumors in people with NF1.
What could go wrong: This is an early-phase trial with only 30 participants, so safety and effectiveness are not yet proven. The drugs may cause side effects, and the combination might not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibromatosis type 1 plexiform neurofibroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS 1 PLEXIFORM NEUROFIBROMA

Contacts and locations

Locations

University of Alabama at Birmingham

Birmingham, Alabama, 34294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.